WINNIPEG, April 28, 2020 /CNW/ - Waverley Pharma Inc.
(the "Company" or "Waverley") announces that due to audit delays
caused by COVID-19 related restrictions, the Company is not
expected to file its annual financial statements and associated
management's discussion and analysis for the year ended
December 31, 2019 ("2019 Financials")
prior to the filing deadline prescribed by National Instrument
51-102 – Continuous Disclosure Obligations ("NI
51-102"). Waverley Pharma will be relying on blanket
orders and similar instruments recently granted by the Canadian
Securities Administrators (including the Manitoba Securities
Commission Blanket Order 52-502 – Temporary Exemption from
Certain Corporate Finance Requirements) (collectively "Blanket
Relief") which provide temporary relief to reporting issuers from
certain requirements of NI 51-102. Specifically, the Company
expects to rely on Blanket Relief to exempt it from filing its 2019
Financials and related CEO and CFO certifications by the filing
deadline of April 29, 2020. The
Company expects to file in advance of the maximum 45-day extension
allowed under the Blanket Relief.
Other than as disclosed in the Company's press releases, there
have not been any material business developments since November 28, 2019, when the Company filed its
interim financial statements and related management's discussion
and analysis for the period ended September
30, 2019.
The Company confirms that its management and other insiders are
subject to an insider trading black-out policy that reflects the
principles in Section 9 of National Policy 11-207 –
Failure-to-File Cease Trade Orders and Revocations in Multiple
Jurisdictions, such that these individuals are in a black-out
period until the commencement of the second trading day after the
2019 Financials have been filed under NI 51-102.
About Waverley Pharma
Waverley Pharma is an emerging pharmaceutical company focused on
the development and commercialization of safe, effective and
affordable therapeutics in the EU and North American market. The
Company, through its subsidiary, is selling two generic oncology
products in the United Kingdom,
namely capecitabine and temozolomide and has three additional
generic products under development. Waverley Pharma is committed to
providing patients with affordable prescription medicines that
lower healthcare costs and provide a better quality of life. For
more information on Waverley Pharma please visit
www.waverleypharma.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
SOURCE Waverley Pharma Inc.
